Trial Number

339-23

Condition

Cystic Fibrosis

Participant Age Range

18 years to 65 years

Participant Gender

Any

Enrolling Participants

Yes

Overview

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability and Efficacy of VX-522 in Subjects 18 Years of age and older with Cystic Fibrosis and CFTR Genotype Not Responsive to CFTR Modulator Therapy

A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF).

Related Clinical Trials

Click on the category you are interested in.

Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.